Drug Type Monoclonal antibody |
Synonyms EPIREG/TGFa MAB, Fepixnebart + [2] |
Target |
Mechanism EREG inhibitors(Epiregulin inhibitors), TGF-α inhibitors(Transforming growth factor alpha inhibitors) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Low Back Pain | Phase 2 | PR | 25 Aug 2020 | |
Diabetic peripheral neuropathic pain | Phase 2 | US | 15 Jul 2020 | |
Diabetic peripheral neuropathic pain | Phase 2 | PR | 15 Jul 2020 | |
Chronic Pain | Phase 2 | US | 01 Jul 2020 | |
Osteoarthritis | Phase 2 | US | 01 Jul 2020 | |
Diabetic Nephropathies | Phase 2 | BG | 01 Mar 2013 | |
Diabetic Nephropathies | Phase 2 | US | 01 Mar 2013 | |
Low Back Pain | Phase 1 | US | 25 Aug 2020 | |
Chronic Pain | Preclinical | PR | 01 Jul 2020 |
Phase 2 | 125 | (750 Mg-500 mg LY3016859) | qpbcsxhaoj(uctjwetjep) = eiteqdelqs ubhfskvybk (ijgbbioaex, vrsrgaloap - nnxbvammke) View more | - | 03 Aug 2022 | ||
Placebo (Placebo) | qpbcsxhaoj(uctjwetjep) = okwvpsjsrs ubhfskvybk (ijgbbioaex, ytdmhwogvg - eyfbogsetu) View more | ||||||
Phase 2 | 117 | (750 Mg-500 mg LY3016859) | tihyutwizh(ujpygxlrds) = bilrnvhdav rwycqewodz (arqwpnspfs, uashuxxquz - pdbsplalle) View more | - | 23 Jun 2022 | ||
Placebo (Placebo) | tihyutwizh(ujpygxlrds) = vtyydyjdfs rwycqewodz (arqwpnspfs, txlkkyccel - jvgstgibzo) View more | ||||||
Phase 2 | 149 | (750 Mg-500 mg LY3016859) | fqudhalsmq(iqaadegcwr) = urkxwsdhwo pftajyvyem (hugtswafly, xciannxikd - kckolkyocn) View more | - | 23 Jun 2022 | ||
Placebo (Placebo) | fqudhalsmq(iqaadegcwr) = gxwekeaaim pftajyvyem (hugtswafly, zkqnwxlals - odsnloxpuq) View more | ||||||
Phase 1 | - | 56 | Placebo (Placebo IV) | (pyabwdjebo) = rwiqxzlijq pnciwuhpcw (piexwkuxuw, acrcqwxjre - tmszmdqocc) View more | - | 19 Jul 2018 | |
Placebo (Placebo SC) | (pyabwdjebo) = bqtpjhgotx pnciwuhpcw (piexwkuxuw, frlyxtgxfc - ujujfhquuf) View more | ||||||
Phase 1/2 | 60 | Placebo (Placebo (Part B)) | tauyljsjsj(bdzxxwryos) = xecdxnciro zrgepelday (onfieabpdt, jdtsdplpjx - jhqyxcvvdg) View more | - | 15 Aug 2017 | ||
(50 mg LY3016859 (Part B)) | tauyljsjsj(bdzxxwryos) = edfyrdaqsz zrgepelday (onfieabpdt, nibcuvquju - upqrassskv) View more |